The Albi hospital center in France has invested in two Paxman scalp cooling systems, offering a new level of support for oncology patients undergoing chemotherapy. The technology aims to minimize hair loss, a deeply distressing side effect of cancer treatment, and represents a commitment to holistic patient care that extends beyond medical intervention. This investment allows the hospital to simultaneously treat four patients with the system, a significant increase in capacity.
The move reflects a substantial growth in the hospital’s oncology services. According to Dr. Nadia Munsch, an oncologist at the center and president of Onco Albi, the service has expanded from 1,000 chemotherapy sessions annually to nearly 8,000 in 2025. “This progression reflects the unwavering commitment of the medical, paramedical, and pharmaceutical teams, who have grown, adapted, and structured themselves to meet the increasing needs of our patients,” Dr. Munsch explained.
But treatment, she emphasizes, is about more than just administering medication. It’s about preserving dignity, self-image, and self-esteem. Hair loss during chemotherapy is a visible sign of illness, a daily reminder of the battle being fought. “The acquisition of two Paxman devices, made possible thanks to your donations, is a step forward, more than just additional equipment,” Dr. Munsch stated. “It’s a message of humanity, a focus on quality of life.”
Understanding Scalp Cooling and Hair Loss During Chemotherapy
Chemotherapy works by targeting rapidly dividing cells, including cancer cells. However, it as well affects other fast-growing cells in the body, such as those in hair follicles. This disruption leads to hair loss, a common and often emotionally devastating side effect of many chemotherapy regimens. Paxman Scalp Cooling, and similar systems like DigniCap, work by reducing the temperature of the scalp immediately before, during, and after chemotherapy administration.
Lowering the scalp temperature constricts blood vessels, reducing the amount of chemotherapy drug that reaches the hair follicles. This can significantly reduce hair loss, allowing many patients to retain much or all of their hair during treatment. The technology has been available for over two decades, with Paxman pioneering the field for over a quarter of a century, supporting patients and minimizing hair loss during chemotherapy in more than 60 countries worldwide.
Paxman and Other Scalp Cooling Options
The Paxman Scalp Cooling System, cleared by the FDA, is one of several options available to patients seeking to mitigate chemotherapy-induced alopecia. Other systems include DigniCap and Amma portable scalp cooling machines by Cooler Heads, also FDA cleared. The Rapunzel Project maintains a list of locations offering these technologies, as well as information on using biomedical freezers for manual cold cap users employing the dry ice method.
The dry ice method, while requiring more effort and assistance, remains a viable option for patients who do not have access to a clinic with a machine-based system. Both freezer and dry ice methods are equally effective, according to experts. The availability of biomedical freezers at some clinics simplifies the process for patients, reducing the cost and logistical challenges of acquiring and handling dry ice.
Addressing Concerns About Scalp Metastasis
Historically, there have been concerns that scalp cooling might increase the risk of scalp metastases, particularly in breast cancer patients. However, recent research has largely dispelled these fears. A study cited by Paxman found no statistical difference in the incidence of scalp metastases between patients who used scalp cooling and those who did not. The study showed a 0.61% incidence of scalp metastases in 1959 patients who used scalp cooling over an average of 43.1 months, compared to 0.41% in 1238 patients who did not, over an average of 84.7 months.
Scalp metastases are rare in breast cancer, generally occurring alongside widespread metastatic disease. Researchers continue to study the long-term effects of scalp cooling to ensure ongoing data relevance.
The Albi Hospital’s Commitment to Innovation
The Albi hospital’s investment in Paxman systems underscores its dedication to innovation and patient-centered care. The hospital’s oncology service has seen remarkable growth, and the addition of these devices demonstrates a commitment to providing the most advanced and supportive treatments available. The acquisition was made possible through donations, highlighting the community’s support for cancer patients in the region.
The hospital’s focus extends beyond simply increasing the volume of chemotherapy sessions. It’s about recognizing the holistic needs of patients and providing resources that enhance their quality of life throughout their cancer journey. The Paxman systems are a tangible expression of that commitment.
The Albi hospital will continue to monitor the efficacy and safety of the Paxman systems, and will share its findings with the wider medical community. Further updates on the hospital’s oncology services can be found on their official website (unconfirmed).
If you or someone you know is undergoing chemotherapy, talk to your oncologist about whether scalp cooling is a suitable option.
Do you have experience with scalp cooling during chemotherapy? Share your thoughts in the comments below.
